Fibrogen announces fda advisory committee to review roxadustat new drug application tentatively scheduled for july 15, 2021

San francisco, april 06, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) announced that the u.s. food and drug administration (fda) has informed the company late today it has tentatively scheduled a cardiovascular and renal drug advisory committee (crdac) on july 15, 2021 to review the new drug application (nda) for roxadustat for the treatment of anemia of chronic kidney disease (ckd) in both dialysis-dependent and non-dialysis-dependent patients.
FGEN Ratings Summary
FGEN Quant Ranking